Story
Neurocrine Biosciences Stock Falls on Vykat Safety Concerns

Neurocrine Biosciences (NASDAQ: NBIX) shares fell 5.8% following a report detailing potential safety issues, including patient deaths, possibly linked to its drug Vykat, which is approved for treating Prader-Willi syndrome.
Details of the Safety Report
According to a Stat News report, a group of physicians and experts specializing in the rare disease has notified clinicians about a series of deaths and severe side effects among patients taking Vykat. The report cites data from the FDA's Adverse Event Monitoring System as of July 31, which includes:
- 7 patient deaths
- More than 100 serious adverse events
The group of experts emphasized that none of the deaths or side effects have been definitively linked to the drug and did not call for Vykat to be withdrawn from the market.
Company Response and Market Impact
AdIn response to the report, Neurocrine CEO Kyle Gano told Stat News, "We don’t see a relationship between the deaths and Vykat XR." Gano added that potential changes to the drug's label or updated instructions for physicians remain "on the table."
Vykat is a treatment for Prader-Willi syndrome, a genetic disorder characterized by a persistent and insatiable hunger. The safety concerns have introduced uncertainty for investors, prompting the significant single-day decline in the company's stock value.
Other Company Developments
Separately, Neurocrine announced positive results from its KINECT-PRO Phase 4 study of INGREZZA for the treatment of tardive dyskinesia. The study, which enrolled 59 patients, demonstrated that the drug improved patient-reported quality of life and functionality, as well as reduced the severity of movements over 24 weeks. The company stated that the safety and tolerability of INGREZZA were consistent with its known profile.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.